BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+0.1%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.95B
AUM Growth
+$2.95B
(-14%)
Cap. Flow
-$147M
Cap. Flow
% of AUM
-4.99%
Top 10 Holdings %
Top 10 Hldgs %
70.08%
Holding
59
New
4
Increased
11
Reduced
13
Closed
6
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$56.2M |
| 2 |
VERV
Verve Therapeutics
VERV
|
$35.3M |
| 3 |
Xencor
XNCR
|
$33.1M |
| 4 |
Revolution Medicines
RVMD
|
$30.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$28.9M |
Top Sells
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$108M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$58.2M |
| 3 |
IDEAYA Biosciences
IDYA
|
$44.7M |
| 4 |
CG Oncology
CGON
|
$37.5M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$26.2M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRD
26
DELISTED
Third Harmonic Bio
THRD
| $24.4M | 0.83% | 2,372,933 -1,993,000 | -46% | -$20.5M |
|
27
Kura Oncology
KURA
$686M
| $22.4M | 0.76% | 2,567,469 -804,292 | -24% | -$7.01M |
|
|
ALLK
28
DELISTED
Allakos
ALLK
| $20M | 0.68% | 16,552,417 | – | – |
|
29
Monte Rosa Therapeutics
GLUE
$296M
| $19.2M | 0.65% | +2,764,471 | New | +$19.2M |
|
30
iTeos Therapeutics
ITOS
| $17.9M | 0.61% | +2,325,000 | New | +$17.9M |
|
31
ESSA Pharma
EPIX
$11.4M
| $15.7M | 0.53% | 8,748,629 | – | – |
|
|
32
4D Molecular Therapeutics
FDMT
$288M
| $14.9M | 0.5% | 2,670,642 -4,712,000 | -64% | -$26.2M |
|
33
RAPT Therapeutics
RAPT
$188M
| $14.6M | 0.49% | +9,237,556 | New | +$14.6M |
|
34
enGene Holdings
ENGN
$236M
| $14M | 0.47% | 2,106,037 -145,000 | -6% | -$964K |
|
35
Repare Therapeutics
RPTX
$71.7M
| $13.5M | 0.46% | 10,333,600 | – | – |
|
36
Forte Biosciences
FBRX
$137M
| $13.5M | 0.46% | 594,282 +475,000 | +398% | +$10.8M |
|
37
Verastem
VSTM
$569M
| $10.9M | 0.37% | 2,100,468 +415,249 | +25% | +$2.15M |
|
38
TScan Therapeutics
TCRX
$102M
| $9.09M | 0.31% | 2,989,474 | – | – |
|
39
Immunic
IMUX
$80.9M
| $8.9M | 0.3% | 8,902,972 | – | – |
|
|
PVLA
40
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $8.36M | 0.28% | 696,555 +438,929 | +170% | +$5.27M |
|
41
Avalo Therapeutics
AVTX
$122M
| $7.7M | 0.26% | 1,036,679 +69,679 | +7% | +$518K |
|
|
IMA
42
ImageneBio, Inc. Common Stock
IMA
$150M
| $6.57M | 0.22% | 4,006,564 -762,600 | -16% | -$1.25M |
|
|
MOLN
43
Molecular Partners
MOLN
$140M
| $6.46M | 0.22% | 1,353,968 +910,747 | +205% | +$4.34M |
|
44
CytomX Therapeutics
CTMX
$336M
| $5.39M | 0.18% | 5,228,461 | – | – |
|
45
Ovid Therapeutics
OVID
$91M
| $3.6M | 0.12% | 3,853,818 | – | – |
|
46
SAB Biotherapeutics
SABS
$19.3M
| $3.51M | 0.12% | 917,826 | – | – |
|
|
VIGL
47
DELISTED
Vigil Neuroscience
VIGL
| $3.08M | 0.1% | 1,813,633 | – | – |
|
|
CBIO
48
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $2.38M | 0.08% | 9,544,262 | – | – |
|
49
Tenax Therapeutics
TENX
$27.3M
| $2.1M | 0.07% | 339,549 | – | – |
|
|
ELEV
50
DELISTED
Elevation Oncology
ELEV
| $1.67M | 0.06% | 2,966,836 | – | – |
|